Thursday, December 19, 2013

Over $116,000 in Revenue Generated through ScripsAmerica’s (SCRC) Joint Venture for November

Pharmaceutical company ScripsAmerica, Inc. has announced that it received and processed $116,987 in November as a result of its recent pharmaceutical distribution joint venture.

For October and November, revenues of $246,781 were generated through the joint venture as a result of ScripsAmerica providing independent pharmacies with wholesale prescription drugs. The combined October and November sales keep ScripsAmerica on a run rate of more than $1.4 million just for this joint venture.

“November proved to be a very strong month in sales for our joint venture, even with the Thanksgiving holiday, therefore keeping pace with previous months,” said ScripsAmerica CEO Bob Schneiderman. “Our run rate continues to be in the $1.5 million range and we expect to increase this rate as our partner continues its growth in the industry. We fully expect that wholesale pharmaceutical distribution to independent pharmacies will remain an area of steady growth for ScripsAmerica and our shareholder value throughout 2014.”

A supplier of prescription, OTC, and nutraceutical drugs, ScripsAmerica delivers pharmaceutical products to a broad range of end users across the healthcare industry, including retail pharmacies, hospitals, long-term care facilities, and government and home care agencies.

For more information, visit www.ScripsAmerica.com

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.


Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net

The Quality Stocks Daily Blog http://blog.qualitystocks.net

The Quality Stocks Daily Videos http://videocharts.qualitystocks.net

 The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net

Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net

No comments: